Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Genentech on Roche's Plans: Our Lips Are Sealed
- Mike Huckman submits: On the Genentech DNA third quarter earnings conference call, analysts, investors and reporters were hoping to get some color on the status of the Roche (RHHBY.PK) play for the rest of DNA it doesn't already own. But from the outset CEO Art Levinson warned, "Don't even...
- External links 2008-10-16
- Dendreon Gets Another Analyst Thumbs-Down
- Mike Huckman submits: I know I blogged as recently as last week that I thought there wouldn't be much reason to write about Dendreon DNDN for awhile, but I couldn't help myself when I got an email Wednesday night from Merriman Curhan Ford, which is launching coverage of DNDN...
- External links 2008-10-17
- Roche: Why No News About Genentech from Earnings Call?
- Mike Huckman submits: Genentech DNA investors who were hoping Roche (RHHBY.PK) would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed. But apparently Roche, which trades on the Swiss...
- External links 2008-10-22
- Genzyme and Osiris Get Together on Stem Cells
- Mike Huckman submits: In a bit of an election-day irony, a pretty significant stem cell deal is grabbing headlines in the biopharma sector. While it definitely took a back seat to the economy this election cycle, stem cell research has long been a hot-button political issue. John McCain supports...
- External links 2008-11-05
- Charles River Labs: Caught in the Credit Crisis Crossfire
- Mike Huckman submits: The so-called contract research organizations (CROs, for short) have been thought to be in the sweet spot of the current biopharma industry cost-cutting trend. More and more drug companies have been farming out an increasing amount of their research to firms like Charles River Labs CRL...
- External links 2008-11-06
- Will Carl Icahn Come to Amylin's Rescue?
- Mike Huckman submits: Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals AMLN. The shares have plummeted from nearly $30 just three months ago to around $7 yesterday. But billionaire activist investor Carl Icahn apparently sees the stock as being on sale. At the end...
- External links 2008-11-17
- Novo Nordisk: Approval of New Diabetes Drug Is Further Postponed
- Mike Huckman submits: Novo Nordisk NVO, a company that has a vested interest in the diabetes market, is out with a new report pegging the cost of treating the disease at nearly a quarter-trillion dollars. According to the "National Changing Diabetes Program" which is sponsored by NVO, the...
- External links 2008-11-18
- Roche Says It'll Still Buy Genentech, Investors Think Otherwise
- Mike Huckman submits: Yesterday morning, the mining company BHP Billiton BHP threw in the towel on its year-and-a-half long hostile attempt to buy its rival Rio Tinto RTP. The company cited the global economy and commodity prices for the pullout. On the heels of that announcement, a reporter from...
- External links 2008-11-25
- Short Interests in Pfizer and Dendreon Decline - Is Bearish Sentiment Dissipating?
- Mike Huckman submits: I know that simply pointing this out will draw the ire of certain Pfizer PFE investors who happen to read my blog, but the fact is that PFE is the only major pharmaceutical company whose short interest is big enough to crack the Barron's Top-40. PFE...
- External links 2008-12-03
- A Bull's on the Loose at Elan
- Mike Huckman submits: Don't look now, but in the first week of the new year shares of Elan ELN are up 30 percent. ELN stock lost nearly three-quarters of its value last year on safety concerns about the multiple sclerosis drug Tysabri, which it shares with Biogen Idec BIIB,...
- External links 2009-01-08
- Was Geron's Announcement Timed?
- Mike Huckman submits: A few days into his term, President Obama appears to have begun to undo another Bush-era policy. He hasn't yet formally lifted the Bush-imposed ban on federal funding of new embryonic stem cell research, but Obama's Food and Drug Administration has already set the stage for...
- External links 2009-01-25
- Sequenom Is Put to the Test
- Mike Huckman submits: I need a break from blogging all-things Pfizer PFE. Sequenom SQNM to the rescue. Wednesday night at an investor/analyst meeting tied to a scientific conference and in a press release, Sequenom unveiled more data on its diagnostic test for Down Syndrome. Out of nearly 900 women...
- External links 2009-01-30
- Why the Drop in Roche's Genentech Bid?
- Mike Huckman submits: Genentech DNA shares dropped three percent Friday or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. Recently, there'd been reports that the Swiss drugmaker, which already has a majority stake in the California biotech, was going to raise the offer...
- External links 2009-02-01
- Roche Is Still Gunning for Genentech
- Mike Huckman submits: Shares of Swiss drugmaker Roche (RHHBY.PK) are trading significantly lower overseas and in over-the-counter activity here in the States after the company reported earnings. But in the U.S., investors are less interested in Roche's numbers and the stock move than they are in what the company...
- External links 2009-02-05
- Biotechs: The Cash Crunch
- Mike Huckman submits: I'm at the annual "BIO CEO" conference in Manhattan today. BIO stands for the Biotechnology Industry Organization. It's the industry's main lobbying group and it puts on this meeting to give mostly baby biotechs a moment in the investor spotlight. A BIO spokesperson says the...
- External links 2009-02-09
- Roche and Genentech: As the Deal Turns
- Mike Huckman submits: What's $23 between friends, er, sparring business partners? The question brings back memories of my grandfather who was of the generation that would hold a grudge for years against a distant relative who still owed him a small amount of money. Anyway, in the ongoing...
- External links 2009-02-11
- Genentech Overtakes Pfizer - Briefly
- Mike Huckman submits: As I was Googling around looking for articles to use as homework for the upcoming Genentech meeting, I stumbled across this nugget on Matthew Herper's "Science Business" blog over at "Forbes." When I wasn't looking, the market value of biotech giant Genentech DNA surpassed the market...
- External links 2009-02-28
- Roche Is Considerably Worse Off Without Genentech
- Mike Huckman submits: While much to my chagrin Genentech DNA isn't matching Roche's (RHHBY.PK) aggressive media strategy in the ongoing takeover battle, during parts of the biotech company's presentation to analysts and investors today, at least two executives pulled no punches. David Ebersman put up a slide titled,...
- External links 2009-03-02
- How Can Both Genentech and Roche Rally?
- Mike Huckman submits: How can investors on both sides of the pond be reading this right? The morning after Genentech's DNA big investor meeting shares of the Swiss drugmaker Roche (RHHBY.PK) rebounded in overseas trading and the American Depository Receipts (ADR) that trade over-the-counter here in the States...
- External links 2009-03-04
- When Will the Genentech Roller Coaster End?
- Mike Huckman submits: On my Thomson Reuters screen on the computer monitor opposite the one I'm using to write this blogpost I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red....
- External links 2009-03-11
- << Previous
- page 1 of 2
- Next >>
Presented by American Express